These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 17296372)

  • 41. Radical prostatectomy: pathology findings in 1001 cases compared with other major series and over time.
    Bott SR; Freeman AA; Stenning S; Cohen J; Parkinson MC
    BJU Int; 2005 Jan; 95(1):34-9. PubMed ID: 15638892
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension.
    Samaratunga H; Duffy D; Yaxley J; Delahunt B
    Hum Pathol; 2010 Feb; 41(2):281-5. PubMed ID: 20004936
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Minimal tumor volume may provide additional prognostic information in good performance patients after radical prostatectomy.
    Guzzo TJ; Vira MA; Neway W; Hwang WT; Tomaszewski J; VanArsdalen K; Wein AJ; Malkowicz SB
    Urology; 2007 Jun; 69(6):1147-51. PubMed ID: 17572204
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Validation of a prediction model for low volume/low grade cancer: application in selecting patients for active surveillance.
    Ochiai A; Trpkov K; Yilmaz A; Donnelly B; Babaian RJ
    J Urol; 2007 Mar; 177(3):907-10. PubMed ID: 17296373
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts.
    Malaeb BS; Rashid HH; Lotan Y; Khoddami SM; Shariat SF; Sagalowsky AI; McConnell JD; Roehrborn CG; Koeneman KS
    Urol Oncol; 2007; 25(4):291-7. PubMed ID: 17628294
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The significance of positive surgical margin in areas of capsular incision in otherwise organ confined disease at radical prostatectomy.
    Chuang AY; Nielsen ME; Hernandez DJ; Walsh PC; Epstein JI
    J Urol; 2007 Oct; 178(4 Pt 1):1306-10. PubMed ID: 17698141
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers.
    Boorjian SA; Karnes RJ; Rangel LJ; Bergstralh EJ; Frank I; Blute ML
    BJU Int; 2008 Feb; 101(3):299-304. PubMed ID: 17922854
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes?
    Thong AE; Shikanov S; Katz MH; Gofrit ON; Eggener S; Zagaja GP; Shalhav AL; Zorn KC
    J Urol; 2008 Dec; 180(6):2436-40. PubMed ID: 18930486
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer.
    Moussa AS; Li J; Soriano M; Klein EA; Dong F; Jones JS
    BJU Int; 2009 Jan; 103(1):43-8. PubMed ID: 18782303
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era?
    Thompson RH; Blute ML; Slezak JM; Bergstralh EJ; Leibovich BC
    J Urol; 2007 Aug; 178(2):459-63; discussion 463. PubMed ID: 17561132
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer.
    Brassell SA; Kao TC; Sun L; Moul JW
    Urology; 2005 Dec; 66(6):1229-33. PubMed ID: 16360448
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens.
    Whittemore DE; Hick EJ; Carter MR; Moul JW; Miranda-Sousa AJ; Sexton WJ
    J Urol; 2008 Feb; 179(2):516-22; discussion 522. PubMed ID: 18076949
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pathological features of Gleason score 6 prostate cancers in the low and intermediate range of prostate-specific antigen level: is there a difference?
    Pelzer AE; Colleselli D; Bektic J; Steiner E; Ramoner R; Mitterberger M; Schwentner C; Schaefer G; Ongarello S; Bartsch G; Horninger W
    BJU Int; 2008 Apr; 101(7):822-5. PubMed ID: 18261154
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumour length of the largest focus predicts prostate-specific antigen-based recurrence after radical prostatectomy in clinically localized prostate cancer.
    Mizuno R; Nakashima J; Mukai M; Okita H; Kosugi M; Kikuchi E; Miyajima A; Nakagawa K; Ohigashi T; Oya M
    BJU Int; 2009 Nov; 104(9):1215-8. PubMed ID: 19389009
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is a positive bladder neck margin truly a T4 lesion in the prostate specific antigen era? Results from the SEARCH Database.
    Buschemeyer WC; Hamilton RJ; Aronson WJ; Presti JC; Terris MK; Kane CJ; Amling CL; Freedland SJ
    J Urol; 2008 Jan; 179(1):124-9; discussion 129. PubMed ID: 17997433
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
    Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer.
    Meeks JJ; Thaxton CS; Loeb S; Roehl KA; Helfand BT; Catalona WJ
    J Urol; 2008 Apr; 179(4):1340-3. PubMed ID: 18289590
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy.
    Rodriguez-Covarrubias F; Larre S; De La Taille A; Abbou CC; Salomon L
    BJU Int; 2008 Feb; 101(3):305-7. PubMed ID: 17941921
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer.
    Davis JW; Nakanishi H; Kumar VS; Bhadkamkar VA; McCormack R; Fritsche HA; Handy B; Gornet T; Babaian RJ
    J Urol; 2008 Jun; 179(6):2187-91; discussion 2191. PubMed ID: 18423725
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of pT2 subdivisions in the TNM staging system for prostate cancer.
    Hong SK; Han BK; Chung JS; Park DS; Jeong SJ; Byun SS; Choe G; Lee SE
    BJU Int; 2008 Nov; 102(9):1092-6. PubMed ID: 18671786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.